Article Details
Retrieved on: 2023-09-11 16:50:47
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Patients were treated with a new bDMARD: adalimumab, infliximab grouped as anti-tumor necrosis factor (TNF) monoclonal antibodies (mAbs) as well ...
Article found on: www.centerforbiosimilars.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here